Novo Nordisk's next generation weight loss drug CagriSema matches Lilly's Zepbound in major trial, but doesn't surpass it CNN Novo Nordisk's New WeightLoss Drug Just Failed a Big TrialSo Why Is It Still Headed to Market? Novo Nordisk: Can CagriSema Show 25% Weight Loss In REDEFINE 1 Trial? Seeking Alpha Novo Next Generation Obesity Shot Falls Short of Lilly Rival Bloomberg Novo Nordisk's share plunges 19.5% post release of weight loss drug CagriSema's trial results Company Business News Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination